USC Norris Comprehensive Cancer Center | Strategic Alliance Partners

November 29, 2024

Researchers find evidence that simultaneously targeting the innate and adaptive immune systems holds promise for treating aggressive colon cancer cases.

August 16, 2024

The new USC Norris location will feature new-to-market technology not yet available in Orange County

June 25, 2024

Jorge J. Nieva, MD, details the role of telemedicine for patients with non–small cell lung cancer and a first-of-its-kind study examining atezolizumab given subcutaneously at home.

June 24, 2024

Dr Agulnik spotlights key updates from across the GIST landscape ahead of GIST Awareness Day on July 13.

June 03, 2024

Lenz discusses the link between HER2 expression and responses with mCRC treatment regimens and how HER2 expression can guide treatment decision-making.

May 31, 2024

A new study may open life-saving opportunities for Hispanic patients, who are one-third less likely to find a fully matched donor from the national registry than white patients.

May 06, 2024

Heinz-Josef Lenz, MD, FACP, discusses the association between HER2 expression and treatment outcomes in metastatic colorectal cancer.

April 25, 2024

HER2 gene expression is associated with prognostic and predictive value in patients with metastatic colorectal cancer.

August 09, 2023

Dr. Chaudhary and Dr. Merin discuss potential areas for exploration and unmet needs in the chronic GvHD treatment landscape.

August 09, 2023

Discussion centered around real-world data following the approval of ruxolitinib as a treatment option for patients with chronic GvHD as well as discussing treatment selection for patients with chronic GvHD, with special consideration for treatment sequencing.

May 01, 2023

Faculty across 4 institutions discuss their participation in a 4-team initiative launched by Stand Up To Cancer® that focuses on expanding access to cancer care and research.

March 23, 2023

To expand access to cancer care and research, Stand Up To Cancer® has launched a 4-team initiative across the United States designed to fill in these gaps in care and remove barriers to entry.

March 22, 2023

Siamak Daneshmand, MD, shed light on the phase 2 THOR-2 study evaluating different cohorts of patients with recurrent NMIBC, key findings from cohorts 2 and 3, and how ongoing research seeks to move the needle forward with novel drug delivery methods.

March 17, 2023

Anthony B. El-Khoueiry, MD, and Chanita Hughes-Halbert, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

March 17, 2023

Christopher W. Ryan, MD, discusses the role of adjuvant pembrolizumab in renal cell carcinoma, the use of immunotherapy-based combinations in the frontline setting for metastatic renal cell carcinoma, and key data presented at the 2023 Genitourinary Cancers Symposium in bladder cancer and prostate cancer.

May 25, 2022

A panel of hepatobiliary tumor experts discuss several pivotal phase 3 clinical trials examining combination approaches that have expanded or are anticipated to expand the treatment armamentarium for treatment-naïve patients with unresectable hepatocellular carcinoma.

February 18, 2022

Heinz-Josef Lenz, MD, discusses the safety and efficacy of nivolumab plus standard of care in patients with metastatic colorectal cancer, shares additional insight from the CheckMate-9X8 trial, and alludes to next steps with further exploring the regimen in specific subsets who appear to derive benefit from this approach.

January 23, 2022

The addition of nivolumab to mFOLFOX6 and bevacizumab failed to demonstrate a statistically significant improvement in progression-free survival vs mFOLFOX6 and bevacizumab alone in previously untreated patients with metastatic colorectal cancer, according to findings from the phase 2/3 CheckMate 9X8 trial.

December 28, 2021

Syma Iqbal, MD, shares the main highlights from an IPC meeting, which centered on the evolving landscapes and importance of implementing best practices for patients with hepatobiliary cancers, locally advanced and advanced pancreatic cancer, advanced gastric/gastroesophageal junction cancer, and metastatic colorectal cancer.

December 24, 2021

With the rapid uptake of novel therapies, including immunotherapy and targeted therapy, shifts in treatment strategies are anticipated in hepatobiliary cancers, locally advanced and advanced pancreatic cancer, gastric/gastroesophageal junction cancers, and metastatic colorectal cancer.